Court Report - Part II - June 4, 2012

[author: Sherri Oslick]

Gavel In an effort to catch up with recently filed biotech and pharma cases, Patent Docs presents this additional installment of Court Report. 

Exelixis, Inc. v. Honorable David J. Kappos
1:12-cv-00574; filed May 29, 2012 in the Eastern District of Virginia

Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,067,436 ("c-Met Modulators and Methods of Use," issued November 29, 2011).  View the complaint here.

Shire Development, LLC et al. v. Mylan Pharmaceuticals, Inc. et al.
8:12-cv-01190; filed May 25, 2012 in the Middle District of Florida

• Plaintiffs:  Shire Development, LLC; Shire Pharmaceutical Development, Inc.; Cosmo Technologies Ltd.; Giuliani International Ltd.
• Defendants:  Mylan Pharmaceuticals, Inc.; Mylan, Inc.

Infringement of U.S. Patent No. 6,773,720 ("Mesalazine Controlled Release Oral Pharmaceutical Compositions," issued August 10, 2004) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Shire's Lialda® (mesalamine, used to induce remission in patients with active, mild to moderate ulcerative colitis).  View the complaint here.

Pfizer Inc. et al. v. Sandoz Inc.
1:12-cv-00654; filed May 24, 2012 in the District Court of Delaware

• Plaintiffs:  Pfizer Inc.; Wyeth LLC; Wyeth Pharmaceuticals Inc.
• Defendant:  Sandoz Inc.

Infringement of U.S. Patent No. 8,026,276 ("Parenteral CCI-779 Formulations Containing Cosolvents, an Antioxidant, and a Surfactant," issued September 27, 2011) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Pfizer's Torisel® (temsirolimus injection, used to treat advanced renal cell carcinoma).  View the complaint here.


Written by:


McDonnell Boehnen Hulbert & Berghoff LLP on:

Popular Topics
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.